Editors' ChoiceCARDIAC AMYLOIDOSIS Breaking through the barrier: Finally hope for patients with cardiac amyloidosis Kory LavineDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. Email: klavine{at}wustl.edu See allHide authors and affiliations Science Translational Medicine 12 Sep 2018:Vol. 10, Issue 458, eaav0337DOI: 10.1126/scitranslmed.aav0337 Kory Lavine Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. Email: Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: klavine@wustl.edu Article Info & Metrics eLetters Article Information vol. 10 no. 458 DOI: https://doi.org/10.1126/scitranslmed.aav0337 Published By: American Association for the Advancement of Science Print ISSN: 1946-6234 Online ISSN: 1946-6242 History: . Copyright & Usage: Copyright © 2018, American Association for the Advancement of Science Author Information Kory LavineDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. Email: klavine{at}wustl.edu Altmetric Article usage Article lifetimeLast 6 monthsThis monthArticle usage: September 2018 to January 2021 AbstractFullPdf Sep 2018323660 Oct 201802180 Nov 201801870 Dec 201831700 Jan 201981220 Feb 2019111070 Mar 201911790 Apr 201941890 May 201963910 Jun 201973750 Jul 201932761 Aug 201941950 Sep 201951580 Oct 201921700 Nov 201921405 Dec 201941421 Jan 202031230 Feb 202091300 Mar 202071061 Apr 202052500 May 20201680 Jun 20200720 Jul 20202900 Aug 20202530 Sep 20202580 Oct 20204650 Nov 20206590 Dec 20206790 Jan 20211390 View Full Text
Breaking through the barrier: Finally hope for patients with cardiac amyloidosis By Kory Lavine Science Translational Medicine12 Sep 2018 Tafamidis improves survival, reduces hospitalizations, and preserves quality of life and exercise tolerance for patients with cardiac amyloidosis.
Breaking through the barrier: Finally hope for patients with cardiac amyloidosis By Kory Lavine Science Translational Medicine12 Sep 2018 Tafamidis improves survival, reduces hospitalizations, and preserves quality of life and exercise tolerance for patients with cardiac amyloidosis.